2025年度，公司持续加大研发投入，同时积极拓展海外市场并强化国内高等级医院的营销力度，助力公 司向大放、向高端、向海外的战略转型，但也导致净利润承压。面对行业结构性升级挑战，公司引进专 业研发技术人员，深化高端医学影像设备的全面布局，尤其是大放品类的CT、MR和DSA。公司聚焦核 心零部件及高性能设备研发，构建"研究一代、储备一代、开发一代"的技术储备格局。同时，公司加速 海外市场的覆盖和深耕，持续完善海外营销组织架构和职能体系，通过实施海外驻点扩容、构建地域性 服务中心等举措，有助提升"一带一路"国家和地区的医疗可及性。 证券之星消息，万东医疗发布业绩预告，预计2025年全年归属净利润亏损1.99亿元至2.57亿元。 公告中解释本次业绩变动的原因为： 2025年度，公司深度参与医疗设备集中采购，为适应市场变化，适时优化了营销策略，通过更具竞争力 的价格方案成功中标影像设备项目，价格调整对毛利率产生了一定影响，导致净利润空间有所压缩。 万东医疗2025年三季报显示，前三季度公司主营收入11.89亿元，同比上升8.73%；归母净利润-2720.98 万元，同比下降123.51%；扣非净利润-4457.54万元 ...

万东医疗表示，2025年，公司深度参与医疗设备集中采购，为适应市场变化，适时优化了营销策略，通 过更具竞争力的价格方案成功中标影像设备项目，价格调整对毛利率产生了一定影响，导致净利润空间 有所压缩。 北京商报讯（记者 丁宁）1月30日晚间，万东医疗（600055）发布2025年业绩预告显示，公司预计2025 年实现归属净利润为-1.99亿元到-2.57亿元。 ...

Core Viewpoint - The performance of asset management is impressive, while the core business is experiencing losses [1][19]. Financial Performance - Jiuan Medical (002432.SZ) forecasts a net profit attributable to shareholders of 2.02 billion to 2.35 billion yuan for 2025, representing a year-on-year growth of 21.05% to 40.83% [4][5]. - For the first three quarters of 2025, Jiuan Medical reported revenue of 1.069 billion yuan, but net profit reached 1.589 billion yuan, indicating that total operating costs of 1.276 billion yuan exceeded revenue [7][13]. - Investment income for the first three quarters was 562 million yuan, with fair value changes contributing 1.251 billion yuan, totaling over 1.8 billion yuan in investment-related income [7]. Asset Management - As of the end of Q3 2025, Jiuan Medical held trading financial assets worth 10.362 billion yuan, primarily in wealth management products, and other investments totaling 13.877 billion yuan, leading to a total asset management portfolio of 24.122 billion yuan [8][10]. - The contribution of asset management to Jiuan Medical's profits is increasing, allowing the company to achieve significant profitability despite a decline in core business revenue [13]. Core Business Challenges - The iHealth product line, which includes smart medical devices, has seen a significant revenue decline, with a 50% drop in revenue to 601 million yuan in the first half of 2025, and a 49% decline in total revenue for the first three quarters [15][16]. - The overall revenue from the iHealth series has decreased from 1.859 billion yuan in 2021 to 601 million yuan in 2025 [17]. Market Reaction - Following the earnings forecast, Jiuan Medical's stock price remained relatively stable, with a price-to-book ratio of 0.89, indicating it is trading below its book value [18].

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 （记者 曾健辉） 每经AI快讯，万东医疗1月30日晚间发布业绩预告，预计2025年度实现归属于母公司所有者的净利润 为-1.99亿元到-2.57亿元，与上年同期相比，将出现亏损。业绩变动主要原因是，2025年度，公司深度 参与医疗设备集中采购，为适应市场变化，适时优化了营销策略，通过更具竞争力的价格方案成功中标 影像设备项目，价格调整对毛利率产生了一定影响，导致净利润空间有所压缩。 ...

强脑科技仿生手现场展示，脑机接口赋能残障群体 1月29日，"为中国经济点赞——企业家之夜"在北京举行。浙江强脑科技有限公司创始人兼CEO韩璧丞出席接受致敬。 活动现场，强脑科技仿生手受益人、假肢售后负责人古月与韩璧丞共同展示了前沿脑机接口技术如何深刻改变残障人士的 生活。古月展示了其佩戴的智能仿生手。他介绍，这只手无需手术植入，可通过直观的意念进行操控，感觉"仿佛我的左手 重新回来了"。随后，他先后完成了抓举10公斤及5公斤哑铃、弹钢琴、远程操控仿生手抓橘子的展示。 【机构观点】 截至2026年1月30日 13:25，医疗设备ETF(159873)换手6.47%，成交1616.21万元。跟踪的中证全指医疗保健设备与服务指数 (H30178)下跌1.22%。成分股方面涨跌互现，澳华内镜领涨10.79%，振德医疗上涨2.65%，华强科技上涨1.83% 截至1月29日，医疗设备ETF(159873)最新规模创近1年新高。医疗设备ETF(159873)近1周份额增长3000.00万份，实现显著 增长。 资金流入方面，医疗设备ETF(159873)近20个交易日内有16日资金净流入，合计"吸金"超1.4亿元。 【产品亮 ...

现存口腔影像设备存在局限：传统牙片机输出二维图像，解剖结构易重叠，邻接面细节模糊，龋齿、牙裂纹等病变易漏诊；锥束CT（口腔CBCT）虽能三维 成像，但往往在分辨率与辐射剂量间难以取得最佳平衡。针对这些痛点，新鸿电子依托自主研发的"冷阴极"X射线源，推出口内三维层析成像系统，提 供"低剂量、快扫描、高清层析成像"解决方案。其核心技术在于X射线源的突破："冷阴极"技术实现常温场发射、瞬间启停，无传统热阴极预热时间与待机 功耗；多焦点分布式设计使单一射线管集成多个独立可控焦点，通过软件切换实现静态多视角快脉冲成像，无需机械运动即可获取多角度图像，解决了速度 瓶颈与运动伪影问题。临床层面，系统采用三维层析重建，影像细节提升40%；在保证低剂量的前提下，扫描时间快至1秒，空间分辨率较锥束CT最高提升 10倍；工作流程易上手，可减少重拍。自2025年9月获批医疗器械注册证以来，该系统已快速落地并与国内头部口腔医院启动临床试用。诊断效能上，临床 数据显示其龋齿检出率较传统牙片机大幅提升，可清晰呈现牙齿断层切片，助力识别根管变异、隐匿的早期龋坏、种植体周围的微小骨变化等细微病变。国 家级认可上，"基于多焦点X射线源的口内三维 ...

Core Insights - ResMed reported $1.42 billion in revenue for the quarter ended December 2025, marking an 11% year-over-year increase and a 2.3% surprise over the Zacks Consensus Estimate of $1.39 billion [1] - The earnings per share (EPS) for the same period was $2.81, compared to $2.43 a year ago, resulting in a 4.59% surprise over the consensus EPS estimate of $2.69 [1] Financial Performance Metrics - U.S., Canada, and Latin America - Devices revenue was $448 million, exceeding the estimated $441.42 million, reflecting an 8.1% year-over-year increase [4] - U.S., Canada, and Latin America - Masks and other revenue reached $387 million, surpassing the average estimate of $367.97 million, with a year-over-year change of 15.7% [4] - Combined Europe, Asia, and other markets - Total revenue was $420.9 million, above the estimated $408.04 million, showing an 11.8% year-over-year increase [4] - Combined Europe, Asia, and other markets - Devices revenue was $278.2 million, slightly above the estimated $275.44 million, with a 9.2% year-over-year change [4] - Combined Europe, Asia, and other markets - Masks and other revenue was $142.7 million, exceeding the average estimate of $132.59 million, reflecting a 17.2% year-over-year increase [4] - U.S., Canada, and Latin America - Total revenue was $835 million, surpassing the estimated $809.39 million, with an 11.5% year-over-year change [4] - Global revenue for Total Sleep and Breathing Health was $1.26 billion, exceeding the estimated $1.2 billion, marking an 11.6% year-over-year increase [4] - Global revenue for Residential Care Software was $166.9 million, slightly below the average estimate of $167.55 million [4] - Global revenue for Total Devices was $726.2 million, exceeding the estimated $716.86 million, with an 8.5% year-over-year change [4] - Global revenue for Total Masks and other was $529.7 million, surpassing the estimated $500.57 million, reflecting a 16.1% year-over-year increase [4] Stock Performance - ResMed shares have returned +7% over the past month, outperforming the Zacks S&P 500 composite's +0.8% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Financial Performance - The company reported Q2 revenues of $464 million, an increase of 11% year-over-year, setting a Q2 record [4][6] - Non-GAAP adjusted EPS reached a record of $2.58, reflecting strong earnings growth [4] - Operating cash flow was solid at $62 million, with expectations for even stronger cash flow in calendar 2026 [4][18] Business Segment Performance - The security division generated revenues of $335 million, up 15% year-over-year, driven by higher service revenues and RF business integration [13][14] - Optoelectronics and Manufacturing division revenues increased 12% year-over-year to $113 million, achieving a new Q2 record [14] - The Healthcare division faced challenges, with sales remaining soft, but the company is focused on long-term value creation through intensified sales efforts [10][11] Market Dynamics - The security division's bookings were lower than expected due to delays from the U.S. government shutdown and international customer pushouts, but the pipeline remains strong [7][24] - The RF business is expanding with a $30 million international order for naval operations and participation in the Golden Dome missile defense initiative, which has a ceiling value of $151 billion [8][9] - The optoelectronics division is benefiting from OEMs diversifying supply chains away from China, with strong demand across various industries [10] Strategic Direction - The company is committed to innovation, as reflected in increased R&D spending, which rose to $19.8 million, or 4.3% of revenues [15] - The company is raising its fiscal 2026 non-GAAP EPS guidance to a range of $10.30-$10.55, indicating 10%-13% year-over-year growth [20] - The focus remains on operational excellence and long-term value creation for shareholders, with plans to invest in key strategic areas [22] Management Commentary - Management expressed confidence in a strong second half of fiscal 2026, supported by a healthy backlog and anticipated cash inflows from Mexico receivables [6][18] - The company acknowledged the impact of the government shutdown on order timing but remains optimistic about future growth opportunities [32][34] - Management highlighted the importance of service revenue growth, which is expected to outpace product revenue growth, contributing to margin expansion [36][37] Other Important Information - The company completed a convertible notes transaction raising $575 million, enhancing liquidity and financial flexibility [19] - The balance sheet remains solid, with net leverage at approximately 2.2 [19] Q&A Session Question: Orders activity in security was softer than expected - Management acknowledged that orders were lower due to delays but emphasized that these opportunities are still alive in the pipeline [24] Question: Details on the IDIQ contract with Golden Dome - Management indicated that while timing is uncertain, they feel well-positioned for future orders related to this significant contract [25][26] Question: Interest expense outlook - Management expects a decrease in interest expense from Q2 to Q3 due to the paydown of the revolver [27] Question: Cash flow expectations - Management anticipates strong free cash flow over the next 12 months, with potential for additional share buybacks [28] Question: Impact of government shutdown on RFP timing - Management noted that the shutdown has pushed some timelines to the right, but they expect some cash flow in the first half of the year [32] Question: Opportunities in the radio frequency business - Management expressed confidence in growth prospects for the RF business, particularly related to the Golden Dome initiative [56] Question: Pipeline for major events like FIFA World Cup and Olympics - Management highlighted their strong position and experience in handling major events, indicating a robust pipeline for upcoming opportunities [60]

Financial Data and Key Metrics Changes - The company reported an 11% headline revenue growth and a 9% growth on a constant currency basis for the second quarter of fiscal year 2026, with GAAP EPS growth of 16% [4][28] - Gross margin increased by 110 basis points year-over-year and by 30 basis points sequentially, reaching 62%-63% for fiscal year 2026 [30][31] - Operating profits increased by 19%, with an operating margin improvement to 36.3% compared to 34% in the prior year [32] Business Line Data and Key Metrics Changes - Global devices revenue experienced high single-digit growth, while masks, accessories, and other revenue saw double-digit growth [4][5] - Residential care software revenue increased by 5% on a constant currency basis, driven by strong performance from the Medifox Dan software vertical [30] Market Data and Key Metrics Changes - Sales in the U.S., Canada, and Latin America increased by 11%, with a 6% increase on a constant currency basis [29] - In Europe, Asia, and other regions, device sales increased by 5% on a constant currency basis, while masks and other sales increased by 8% [29] Company Strategy and Development Direction - The company aims to build a leading digital health ecosystem encompassing sleep health, breathing health, and healthcare technology delivered in the home [8] - Continued focus on operational excellence and innovation, with a commitment to R&D investments of 6%-7% of revenues and SG&A investments of 19%-20% [26][31] - The company is expanding its digital sleep health concierge capabilities and enhancing its manufacturing footprint to improve delivery efficiency [10][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in re-accelerating growth in Europe, Asia, and the rest of the world, with expectations of sustainable high single-digit growth in the residential care software business by fiscal year 2027 [5][6] - The company is closely monitoring the global trade environment and regulatory landscape, with positive implications from recent developments in competitive bidding programs [21][23] Other Important Information - The company returned $263 million to shareholders through dividends and $175 million in share repurchases during the quarter, with plans to increase share repurchases to over $600 million for fiscal year 2026 [34][26] - The launch of new AI-enabled products, such as Comfort Match, is expected to enhance patient adherence to therapy [12][19] Q&A Session Summary Question: Strong US mask number and impact of Virtuox - Management confirmed that the strong growth in masks includes contributions from Virtuox, but even without it, there was solid double-digit growth in masks and accessories [36][38] Question: Update on GLP-1 landscape and its impact - Management noted a 10%-11% higher start rate for CPAP therapy among patients with GLP-1 prescriptions, indicating a motivated patient group [39][41] Question: SG&A growth ahead of revenue growth - Management explained that the SG&A growth includes impacts from the Virtuox acquisition and promotional activities, but underlying growth is tracking closely with revenue [43] Question: Impact on patient funnel stages - Management highlighted significant progress in the top of the funnel due to increased awareness from Big Pharma and tech, while focusing on scaling home sleep apnea testing [45][47] Question: Potential return of Philips to the US market - Management expressed confidence in competing effectively against Philips, noting that they have been performing well in various markets despite Philips' presence [60][62]

最新公告列表 《迈得医疗工业设备股份有限公司2026年第一次临时股东会会议资料》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月29日收盘，迈得医疗（688310）报收于16.04元，较前一交易日下跌2.08%，最新总市值 为26.66亿元。该股当日开盘16.6元，最高16.89元，最低15.99元，成交额达9773.29万元，换手率为 3.59%。 近日，迈得医疗工业设备股份有限公司披露《2026年第一次临时股东会会议资料》，拟向控股子公司浙 江迈得顺隐形眼镜有限公司提供总额不超过人民币1亿元的财务资助，资助期限为自股东会审议通过之 日起3年内，借款利率参照一年期LPR，利息按实际借款占用天数计算。迈得顺可循环使用额度。公司 实际控制人林军华、持股5%以上股东陈万顺为本次资助提供连带责任保证。本次资助事项构成关联交 易，不构成重大资产重组。董事会已提请股东会授权管理层办理相关协议签署及款项支付等事宜。 ...